← back to search

Laura A. VanBlargan

National Institutes of Health · US
🔎 Find collaborators in Infectious Diseases · Public Health, Environmental and Occupational Health →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Infectious Diseases · Public Health, Environmental and Occupational Health
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Mosquito-borne diseases and control, and SARS-CoV-2 detection and testing.
h-index
31
citations
7,819
works
71
NIH funding
primary concept
Biology
email

Recent publications

Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8
Cell 2023cited by 37position: middledoi
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Nature Medicine 2022cited by 764position: firstdoi
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
Science Translational Medicine 2022cited by 117position: middledoi
Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants
Nature Biotechnology 2022cited by 32position: middledoi
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Cell Reports 2022cited by 16position: middledoi
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature 2021cited by 1,200position: middledoi
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Nature Medicine 2021cited by 1,014position: middledoi
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Cell Host & Microbe 2021cited by 847position: middledoi
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature 2021cited by 260position: middledoi
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature 2021cited by 213position: middledoi
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors
Med 2021cited by 36position: middledoi
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Cell 2020cited by 624position: middledoi
Dengue viruses cluster antigenically but not as discrete serotypes
Science 2015cited by 246position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Diamond · Infectious Disease Research Institute5 papers (2021–2023)Daved H. Fremont · University of Chicago3 papers (2021–2023)John M. Errico · VIR Biotechnology (United States)3 papers (2021–2023)Rita E. Chen · Saint Louis University2 papers (2021–2021)Ali H. Ellebedy · Harvard University2 papers (2021–2021)John E. Bowen · Cleveland Clinic1 papers (2022–2022)Ahmed O. Hassan · Washington University in St. Louis1 papers (2023–2023)Zhuoming Liu · Washington University in St. Louis1 papers (2021–2021)Rachel M. Presti · The Ohio State University1 papers (2021–2021)Haiyan Zhao · Hubei University of Medicine1 papers (2021–2021) · 1 papers (2022–2022)James E. Crowe · Vanderbilt University Medical Center1 papers (2022–2022)Matthew J. Gorman · Colorado State University1 papers (2021–2021)Lance Stewart · Joint Center for Structural Genomics1 papers (2022–2022)David Baker · Howard Hughes Medical Institute1 papers (2022–2022) · 1 papers (2021–2021)Mark H. Wener · Pacific Northwest Diabetes Research Institute1 papers (2022–2022)Minh N. Pham · Curtin University1 papers (2022–2022)Sathvik Palakurty · Washington University in St. Louis1 papers (2023–2023)Bradley Whitener · Vir Biotechnology (Switzerland)1 papers (2023–2023)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Infectious Diseases · Public Health, Environmental and Occupational Health →